Moreover, Zhang et al suggested that in pancreatic cancer, gemcitabine treatment activated NF‐κB signalling pathway by increasing the nuclear translocation of NF‐κB p65 and then promoted stemness phenotypic characteristics, such as enhanced sphere formation, migration and chemoresistance as well as the expression of stemness markers, including Sox2, Nanog and Bmi1.17 This evidence concerns the gene NFKB1 and familial pancreatic carcinoma.